Quanterix Corp
$ 3.30
-5.71%
20 Apr - close price
- Market Cap 164,290,000 USD
- Current Price $ 3.30
- High / Low $ 3.56 / 3.23
- Stock P/E N/A
- Book Value 6.33
- EPS -2.51
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.34 %
- 52 Week High 8.77
- 52 Week Low 3.23
About
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advance precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the regions from Asia Pacific. The company is headquartered in Billerica, Massachusetts.
Analyst Target Price
$6.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-10 | 2025-08-07 | 2025-05-05 | 2025-02-26 | 2024-11-12 | 2024-08-08 | 2024-05-07 | 2024-02-29 | 2023-11-06 | 2023-08-07 | 2023-05-09 |
| Reported EPS | -0.47 | -0.73 | -0.77 | -0.53 | -0.3 | -0.2186 | -0.25 | -0.26 | -0.33 | -0.21 | -0.16 | -0.16 |
| Estimated EPS | -0.4322 | -0.46 | -0.43 | -0.432 | -0.254 | -0.2443 | -0.27 | -0.31 | -0.32 | -0.37 | -0.38 | -0.38 |
| Surprise | -0.0378 | -0.27 | -0.34 | -0.098 | -0.046 | 0.0257 | 0.02 | 0.05 | -0.01 | 0.16 | 0.22 | 0.22 |
| Surprise Percentage | -8.746% | -58.6957% | -79.0698% | -22.6852% | -18.1102% | 10.5199% | 7.4074% | 16.129% | -3.125% | 43.2432% | 57.8947% | 57.8947% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.31 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QTRX
2026-04-20 08:38:32
Quanterix Corporation is launching its new Content Innovation Engine at the American Association for Cancer Research (AACR) Annual Meeting 2026. This engine integrates Akoya Biosciences' spatial biology platform with Quanterix's ultra-sensitive immunoassay development using SIMOA technology, providing a biology-first approach to cancer research. Quanterix will also introduce new offerings like the IO60 Spike-In Module for checkpoint therapy and tertiary lymphoid structure markers, and the PhenoCode Molecular Barcoding Kit for antibody barcoding.
2026-04-18 05:38:53
Wall Street Zen has downgraded Quanterix (NASDAQ:QTRX) from a "hold" to a "sell" rating, contributing to a "Reduce" consensus rating and an average price target of $8.00. The company recently missed quarterly EPS estimates but exceeded revenue expectations, remaining unprofitable with a forecasted negative EPS for the current fiscal year. Despite the downgrade, institutional investors hold a significant portion of the stock, and several large funds increased their stakes in the last quarter.
2026-04-17 20:59:29
Quanterix COO Michael Francis Miller exercised 1,558 Restricted Stock Units (RSUs) into common stock on April 15, 2026. To cover tax obligations from these vesting events, 467 shares were withheld and disposed of at $3.60 per share. Following these transactions, Miller directly holds 32,522 shares of Quanterix common stock.
2026-04-17 20:58:29
Quanterix (NASDAQ: QTRX) CFO Sriram Vandana received shares through the vesting of restricted stock units (RSUs) on April 15, 2026. A total of 1,833 shares across three tranches converted into common stock, with a portion withheld for tax obligations rather than being sold in the open market. Following these transactions, the CFO directly holds 28,713 shares of Quanterix common stock.
2026-04-17 15:10:29
Quanterix (QTRX) has launched AidaBREAST, a multi-omic assay designed to assess locoregional recurrence risk and potential benefits of radiation therapy for early-stage invasive breast cancer. This innovation, built on the Akoya PhenoImager HT platform, aims to provide comprehensive tumor biology insights. Despite the significant product launch, Quanterix faces financial challenges with a moderate GF Score™ of 66/100, low profitability, and its stock trading near a 10-year low.
2026-04-17 14:10:29
Quanterix and PreludeDX have highlighted AidaBREAST, a new multi-omic assay designed to predict locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer. Developed on the Akoya PhenoImager HT platform, the assay leverages spatial biology and AI to provide insights into tumor biology. This tool offers clinicians a unique capability to inform treatment decisions by predicting both recurrence likelihood and the efficacy of radiation therapy for specific patients.
